• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Imjudo (tremelimumab) plus Imfinzi (durvalumab)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Imjudo (tremelimumab) plus Imfinzi (durvalumab)

  • Profile

Profile

Contact Information

Contact: AstraZeneca
Website: www.imfinzi.com

Currently Enrolling Trials

    Show More

    Imjudo (tremelimumab) plus Imfinzi (durvalumab) - 2 indications

    Scroll down for additional information on each indication:

    • Adult patients with unresectable hepatocellular carcinoma; approved October of 2022
    • Adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC); approved November of 2022

    General Description

    Imjudo (tremelimumab) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody. Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody.

    The combination is specifically indicated for:

    • the treatment of adult patients with unresectable hepatocellular carcinoma
    • use in combination with platinum-based chemotherapy for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations

    The combination of Imjudo/Imfinzi is supplied as an intravenous infusion administered over 60 minutes after dilution. Scroll down for specific dosing recommendations for each indication.

    Mechanism of Action

    Imjudo (tremelimumab) is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo blocks the activity of CTLA-4, contributing to T-cell activation, priming the immune response to cancer and fostering cancer cell death.

    Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses.

    Side Effects

    Adverse reactions may include, but are not limited to, the following:

    • rash
    • diarrhea
    • fatigue
    • pruritus
    • musculoskeletal pain
    • abdominal pain
    • Laboratory abnormalities (≥ 40%) including:  AST increased, ALT increased, hemoglobin decreased, sodium decreased, bilirubin increased, alkaline phosphatase increased, and lymphocytes decreased

    Indication 1 - unresectable hepatocellular carcinoma

    approved October of 2022

    Dosing/Administration

    The recommended dose is based on weight:

    • Weight 30 kg and more: Imjudo 300 mg as a single dose in combination with durvalumab 1,500 mg at Cycle 1/Day 1, followed by durvalumab as a single agent every 4 weeks
    • Weight less than 30 kg: Imjudo 4 mg/kg as a single dose in combination with durvalumab 20 mg/kg at Cycle 1/Day 1, followed by durvalumab as a single agent every 4 week

    Clinical Trial Results

    The FDA approval Imjudo (tremelimumab) plus Imfinzi (durvalumab) was based on results from the phase 3 HIMALAYA trial. Patients treated with the combination of Imjudo and Imfinzi experienced a 22% reduction in the risk of death versus Bayer's Nexavar (sorafenib), a standard-of-care multi-kinase inhibitor. Approximately 31% of patients treated with the combination were still alive after three years, with 20% of patients treated with sorafenib still alive at the same duration of follow-up.

    Indication 2 -  Stage IV (metastatic) NSCLC

    approved November of 2022

    Dosing/Administration

    The recommended dose is based on weight:

    Weight ≥ 30 kg: Imfinzi 1,500 mg every 3 weeks in combination with Imjudo (tremelimumab) 75 mg and platinum-based chemotherapy for 4 cycles, and then administer Imfinzi 1,500 mg every 4 weeks as a single agent with histology-based pemetrexed maintenance therapy every 4 weeks, and a fifth dose of Imjudo 75 mg in combination with Imfinzi dose 6 at week 16 

    Weight < 30 kg: 20 mg/kg every 3 weeks in combination with Imjudo1 mg/kg and platinum-based chemotherapy, and then administer Imfinzi 20 mg/kg every 4 weeks as a single agent with histology-based pemetrexed therapy every 4 weeks, and a fifth dose of Imjudo 1 mg/kg in combination with Imfinzi dose 6 at week 1.

    Clinical Trial Results

    The approval was based on the results from the POSEIDON phase 3 trial. Patients treated with a limited course of five cycles of the anti-CTLA-4 antibody Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a range of chemotherapy options. An estimated 33% of patients were alive at two years versus 22% for chemotherapy. This treatment combination also reduced the risk of disease progression or death by 28% compared to chemotherapy alone. 

    Approval Date: 2022-10-01
    Company Name: AstraZeneca
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing